Retension Pharmaceuticals, Inc. (NASDAQ: RTSN), a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular diseases, has priced an upsized initial public offering of 3,750,000 shares of common stock at $12 per share, raising expected gross proceeds of $45 million before underwriting discounts and expenses. The company also granted underwriters a 30-day option to purchase up to an additional 562,500 shares. Shares were expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, with the offering scheduled to close on or about Oct. 13, subject to customary conditions.
The upsized offering signals strong investor demand for Retension’s lead candidate, RTN-001, which is in development for patients with uncontrolled and resistant hypertension. The company intends to use the net proceeds, together with existing cash, to complete its Phase 2b clinical trial of RTN-001 and to prepare for, support, and advance a planned Phase 3 trial. Remaining funds will be allocated to general corporate purposes and operating expenses. For investors tracking the company’s progress, Retension (NASDAQ: RTSN) offers a dedicated market research page.
The capital infusion is critical because Phase 2b and Phase 3 trials are the most expensive and time-consuming stages of drug development. Successfully completing these trials is essential for Retension to seek regulatory approval for RTN-001. The IPO proceeds provide the company with the financial runway to advance its lead program without relying on potentially dilutive financing or partnership deals in the near term. Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are serving as joint bookrunning managers, with Titan Partners acting as lead manager. The full press release is available at https://ibn.fm/uko0m.
Retension’s focus on uncontrolled and resistant hypertension addresses a significant unmet medical need. Many patients fail to achieve target blood pressure with existing therapies, putting them at higher risk for heart attack, stroke, and kidney disease. A successful new treatment could capture a substantial market share and improve patient outcomes. More information about the company is available at https://www.retensionpharmaceuticals.com/.
The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides editorial syndication to 5,000+ outlets and other services. For full terms and disclaimers, see https://www.InvestorWire.com/Disclaimer.
